These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3763484)

  • 1. Action of fibrinopeptides A and B on the central dopaminergic system of rats pretreated with indomethacin.
    Swiderska D; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1986; 38(1):21-8. PubMed ID: 3763484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participation of prostaglandins E2 and F2 alpha in the action of fibrinopeptides A and B on the central dopaminergic system.
    Swiderska D; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1986; 38(1):29-39. PubMed ID: 3463941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further studies on the effect of fibrinopeptides A and B on the central nervous system.
    Bernacka I; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1981 Nov; 33(4):407-14. PubMed ID: 7329866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the role of catecholamines in the action of fibrinopeptides A and B in the circulatory system of rats.
    Antecka-Genadiew E; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1983; 35(5):367-76. PubMed ID: 6664939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of some prostaglandins in the interaction of fibrinogen degradation products (FDP) with central dopamine receptors of rats.
    Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1979; 31(5):473-80. PubMed ID: 575732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of fibrinopeptides A and B with dopaminergic receptors in central nervous system.
    Wawrzyniuk I; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1979; 31(4):365-72. PubMed ID: 574959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of fibrinopeptides A and B on the circulatory action of dopamine.
    Barczak-Osińska J; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1983; 35(4):285-92. PubMed ID: 6664936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of products of degradation of fibrinogen A and B on the arterial blood pressure in the rat.
    Barczak-Osińska J; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1983; 35(4):279-83. PubMed ID: 6664935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of bovine fibrinopeptides on the central action of chlorpromazine and amphetamine in rats.
    Buczko W
    Acta Neurobiol Exp (Wars); 1976; 36(4):447-54. PubMed ID: 983820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiotensin on the central action of dopamine.
    Braszko J; Wiśniewski K
    Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of prostaglandins in the action of kinins on the central dopaminergic system in the rat. I. The action of kinins on the central dopaminergic system after pretreatment with indomethacin.
    Kościelak M; Moniuszko-Jakoniuk J; Wiśniewski K
    Pol J Pharmacol Pharm; 1980; 32(3):343-56. PubMed ID: 6912578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some pharmacological and biochemical effects of fibrinopeptides A and B in the circulatory system of rats.
    Antecka-Genadiew E; Buczko W; Stasiak A; Maciejewski A; Wiśniewski K
    Pol J Pharmacol Pharm; 1983; 35(5):359-66. PubMed ID: 6664938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of insulin hypoglycemia on central dopaminergic structures of the rat.
    Kleinrok Z; Ossowska G; Stelmasiak M; Juszkiewicz M
    Pol J Pharmacol Pharm; 1983; 35(6):489-95. PubMed ID: 6377282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central action of phenylethylamine in rats.
    Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1981; 33(1):59-71. PubMed ID: 7196039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of calcium channel blockers on the effects of haloperidol and phenamine in mice and rats].
    Kozlovskiĭ VL; Prakh'e IV; Kenunen OG
    Eksp Klin Farmakol; 1996; 59(3):12-5. PubMed ID: 8974575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of antineoplaston A5 on the central dopaminergic structures.
    Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z
    Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of fibrinogen degradation products on the action of amphetamine in the central nervous system.
    Zwoliński J; Buczko W
    Pol J Pharmacol Pharm; 1977; 29(3):313-9. PubMed ID: 560684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central action of narcotic analgesics. I. Catalepsy and stereotypy in rats and narcotic analgesics.
    Malec D; Fidecka S; Langwiński R
    Pol J Pharmacol Pharm; 1977; 29(3):177-93. PubMed ID: 560683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.